EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Model for end-stage liver disease-3.0 vs. model for end-stage liver disease-sodium: mortality prediction in Korea

Jeong Han Kim, Yong Joon Cho, Won Hyeok Choe, So Young Kwon, Byung-Chul Yoo

The Korean Journal of Internal Medicine · 2024

DOI: 10.3904/kjim.2023.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Korean Journal of Internal Medicine, 2024. Verfasst von Jeong Han Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: End Stage Liver Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: The model for end-stage liver disease (MELD) serves as an indicator for short-term mortality among patients diagnosed with liver cirrhosis (LC) and is used to prioritize patients for liver transplantation. In 2021, the updated version of MELD, MELD-3.0, was introduced to improve the accuracy of the mortality prediction of MELD. Therefore, this study aimed to compare the efficacy of MELD 3.0 and MELD-Na in predicting mortality among Korean patients with LC.

Methods

A retrospective review was conducted using the medical records of patients diagnosed with LC who were admitted to Konkuk University Hospital From 2011 to 2021. The study calculated the predictive values of MELD-Na and MELD-3.0 for 3- and 6-months mortality using the area under the receiver operating curve (AUROC) and compared the results using the DeLong test.

Results

Of the 3,034 patients enrolled in the study, 339 (11.2%) died within 3 months and 421 (14.4%) died within 6 months. The AUROCs values for predicting 3 months mortality were 0.846 for MELD-Na and 0.851 for MELD-3.0. The corresponding AUROC values for predicting 6 months mortality were 0.843 for MELD-Na and 0.848 for MELD-3.0. MELD-3.0 exhibited better discrimination ability than MELD-Na for both 3 (p = 0.03) and 6 months mortality (p = 0.01).

Conclusions

Our study found a significant difference between the performance of MELD-3.0 and MELD-Na in Korean patients with LC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

End Stage Liver DiseaseHumansPrognosisSodiumPredictive Value of TestsSeverity of Illness IndexLiver CirrhosisRetrospective StudiesRepublic of KoreaROC Curve

Stichwörter der Autor:innen

CreatinineEnd stage liver diseaseLiver cirrhosisMortalitySodium

Substanzen

Sodium

Autor:innen und Institutionen

  • Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.
  • Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea.

Zitieren

APA

Kim, J. H., Cho, Y. J., Choe, W. H., Kwon, S. Y., & Yoo, B. C. (2024). Model for end-stage liver disease-3.0 vs. model for end-stage liver disease-sodium: mortality prediction in Korea. The Korean Journal of Internal Medicine. https://doi.org/10.3904/kjim.2023.005

Vancouver

Kim JH, Cho YJ, Choe WH, Kwon SY, Yoo BC. Model for end-stage liver disease-3.0 vs. model for end-stage liver disease-sodium: mortality prediction in Korea. The Korean Journal of Internal Medicine. 2024. doi:10.3904/kjim.2023.005

BibTeX
@article{Kim2024,
  author = {Kim, Jeong Han and Cho, Yong Joon and Choe, Won Hyeok and Kwon, So Young and Yoo, Byung-Chul},
  title = {Model for end-stage liver disease-3.0 vs. model for end-stage liver disease-sodium: mortality prediction in Korea},
  journal = {The Korean Journal of Internal Medicine},
  year = {2024},
  doi = {10.3904/kjim.2023.005}
}
Kostenlos starten →